<DOC>
	<DOCNO>NCT01412671</DOCNO>
	<brief_summary>This study early access program 'Nexavar post-marketing surveillance ( PMS ) renal cell carcinoma ( RCC ) Japan ' regulatory , local prospective observational study patient unresectable advanced RCC real-life practice condition . The objective study ass safety effectiveness Nexavar limit site join clinical trial Nexavar , available market . The enrollment period 2 month , patient receive Nexavar recruit follow one year since start Nexavar administration . The data study integrate Nexavar PMS data analyze report alone .</brief_summary>
	<brief_title>Nexavar Post-marketing Surveillance RCC Japan : Early Access Program</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients receive Nexavar unresectable advance renal cell carcinoma Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Nexavar</keyword>
	<keyword>unresectable advance renal cell carcinoma</keyword>
</DOC>